WoundReference improves clinical decisions
 Choose the role that best describes you
Fonder MA, Cummins DL, Ehst BD, Anhalt GJ, Meyerle JH, et al.
Journal of burns and wounds. Date of publication 2006 Nov 20;volume 5():e8.
1. J Burns Wounds. 2006 Nov 20;5:e8. Adalimumab therapy for recalcitrant pyoderma gangrenosum. Fonder MA(1), Cummins DL, Ehst BD, Anhalt GJ, Meyerle JH. Author information: (1)Department of Dermatology, Johns Hopkins Medical Institutions, Baltimore, MD, USA. OBJECTIVE: To describe a patient with treatment-refractory pyoderma gangrenosum and the outcome of a novel therapeutic approach. METHODS: Case report and review of the literature. RESULTS: A patient with inflammatory bowel disease developed severe pyoderma gangrenosum while receiving treatment with the chimeric anti-TNF-alpha antibody infliximab. Despite subsequent trials of numerous immunosuppressive and immunomodulatory medications, the dermatologic disease progressed. The patient's ulcers finally resolved when treatment with adalimumab, a fully humanized monoclonal antibody specific for TNF-alpha, was initiated. CONCLUSIONS: We report a novel application of the TNF-alpha inhibitor, adalimumab, in the treatment of pyoderma gangrenosum. PMCID: PMC1687150 PMID: 17149453
Appears in following Topics:
Pyoderma Gangrenosum - Treatment